Literature DB >> 22009849

Review of current treatment of sacral chordoma.

Kang-wu Chen1, Hui-lin Yang, Yugandhar Kandimalla, Jia-yong Liu, Gen-lin Wang.   

Abstract

Chordoma is a relatively rare, locally aggressive tumor which is known to arise from embryonic remnants of the notochord and to occur exclusively along the spinal axis, with a predilection for the sacrum. Although chordoma typically presents as a single lesion, a few cases of metastasis have been reported and the prognosis of such patients may be poor. Chordomas are slowly growing tumors with insidious onset of symptoms, making early diagnosis difficult. Recent improvements in imaging have provided valuable information for early diagnosis. The optimal treatment for sacral chordoma is en bloc sacral resection with wide surgical margins. Improvement in surgical techniques has widened the opportunities to provide effective treatment. However, the effects of adjuvant treatment options are still both unclear and controversial. Substantial progress has been made in the study of molecular-targeted therapy. The authors review the current surgical and adjuvant treatment modalities, including molecular-targeted therapy, available for management of sacral chordoma.
© 2009 Tianjin Hospital and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 22009849      PMCID: PMC6583561          DOI: 10.1111/j.1757-7861.2009.00027.x

Source DB:  PubMed          Journal:  Orthop Surg        ISSN: 1757-7853            Impact factor:   2.071


  11 in total

Review 1.  Variables affecting functional improvement in chordoma patients admitted to an inpatient rehabilitation facility: A retrospective review.

Authors:  Sasha E Knowlton; Richard Goldstein; Kevin C O'Connor; Joseph Schwab; Francis Hornicek; Ross Zafonte
Journal:  J Spinal Cord Med       Date:  2017-05-02       Impact factor: 1.985

2.  "En bloc" resection of sacral chordomas by combined anterior and posterior surgical approach: a monocentric retrospective review about 29 cases.

Authors:  Arnaud Dubory; Gilles Missenard; Benoît Lambert; Charles Court
Journal:  Eur Spine J       Date:  2014-01-28       Impact factor: 3.134

3.  Sacral chordoma: challenging for resection margin.

Authors:  Seung-Hyun Lee; Byung-Kwon Ahn
Journal:  Ann Coloproctol       Date:  2014-06

4.  Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma.

Authors:  Ming Zhou; Kangwu Chen; Huilin Yang; Genlin Wang; Jian Lu; Yiming Ji; Chunshen Wu; Chao Chen
Journal:  J Neurooncol       Date:  2013-10-18       Impact factor: 4.130

5.  Low expression of PHLPP1 in sacral chordoma and its association with poor prognosis.

Authors:  Hao Chen; Kai Zhang; Guizhong Wu; Dawei Song; Kangwu Chen; Huilin Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

6.  Case report: Successful treatment of recurrent chordoma and bilateral pulmonary metastases following an 11-year disease-free period.

Authors:  Cherie P Erkmen; Richard J Barth; Vignesh Raman
Journal:  Int J Surg Case Rep       Date:  2014-05-02

7.  Chondromyxoid fibroma of the sacrum: A case report and literature review.

Authors:  Tanya Minasian; Chad Claus; Omid R Hariri; Zhe Piao; Syed A Quadri; Robert Yuhan; Darren Leong; Vartan Tashjian
Journal:  Surg Neurol Int       Date:  2016-05-17

Review 8.  Chordoma: The Quest for Better Treatment Options.

Authors:  Christopher R Heery
Journal:  Oncol Ther       Date:  2016-03-03

9.  Risk Factors Associated with Reconstructive Complications Following Sacrectomy.

Authors:  Emma D Vartanian; Jeremy V Lynn; David P Perrault; Erik M Wolfswinkel; Andreas M Kaiser; Ketan M Patel; Joseph N Carey; Patrick C Hsieh; Alex K Wong
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-11-05

10.  Active receptor tyrosine kinases, but not Brachyury, are sufficient to trigger chordoma in zebrafish.

Authors:  Gianluca D'Agati; Elena María Cabello; Karl Frontzek; Elisabeth J Rushing; Robin Klemm; Mark D Robinson; Richard M White; Christian Mosimann; Alexa Burger
Journal:  Dis Model Mech       Date:  2019-07-16       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.